NeuroBo Pharmaceuticals Inc expected to post a loss of 89 cents a share - Earnings Preview

Reuters11-08

NeuroBo Pharmaceuticals Inc <nrbo.oq> expected to post a loss of 89 cents a share - Earnings Preview </nrbo.oq>

NeuroBo Pharmaceuticals Inc NRBO.OQ NRBO.O is expected to show no change in quarterly revenue when it reports results for the period ending December 31 2024
LSEG's mean analyst estimate for NeuroBo Pharmaceuticals Inc is for a loss of 89 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 22.1% in the last three months.
Wall Street's median 12-month price target for NeuroBo Pharmaceuticals Inc is $22.00, above its last closing price of $2.68.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Jan. 1 0001	-0.77	-0.73	-0.55	Beat	24.7
Jan. 1 0001	-1.06	-1.12	-1.85	Missed	-64.7
Mar. 31 2024	-3.79	-3.63	-1.32	Beat	63.6
Dec. 31 2023	-0.79	-0.78	-2.28	Missed	-190.4
Jan. 1 0001	-0.86	-0.86	-0.72	Beat	15.9
Jun. 30 2023	-1.01	-1.01	-0.16	Beat	84.1
Mar. 31 2023		-5.04	-0.77	Beat	84.8
Dec. 31 2022	-9.60	-9.60	-14.56	Missed	-51.7

This summary was machine generated November 8 at 15:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481932483?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 23:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481932483","market":"us","top_or_hot":-1,"title":"NeuroBo Pharmaceuticals Inc  expected to post a loss of 89 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>NeuroBo Pharmaceuticals Inc <nrbo.oq> expected to post a loss of 89 cents a share - Earnings Preview </nrbo.oq></title></head><body><ul><li><p>NeuroBo Pharmaceuticals Inc <span>NRBO.OQ</span> <span>NRBO.O</span> is expected to show no change in quarterly revenue when it reports  results  for the period ending December 31 2024</p></li><li></li><li><p>LSEG's mean analyst estimate for NeuroBo Pharmaceuticals Inc is for a loss of 89 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts had risen by about 22.1% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for NeuroBo Pharmaceuticals Inc is $22.00, above its last closing price of $2.68. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jan. 1 0001</p></td><td><p>-0.77</p></td><td><p>-0.73</p></td><td><p>-0.55</p></td><td><p>Beat</p></td><td><p>24.7</p></td></tr><tr><td><p>Jan. 1 0001</p></td><td><p>-1.06</p></td><td><p>-1.12</p></td><td><p>-1.85</p></td><td><p>Missed</p></td><td><p>-64.7</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-3.79</p></td><td><p>-3.63</p></td><td><p>-1.32</p></td><td><p>Beat</p></td><td><p>63.6</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-0.79</p></td><td><p>-0.78</p></td><td><p>-2.28</p></td><td><p>Missed</p></td><td><p>-190.4</p></td></tr><tr><td><p>Jan. 1 0001</p></td><td><p>-0.86</p></td><td><p>-0.86</p></td><td><p>-0.72</p></td><td><p>Beat</p></td><td><p>15.9</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-1.01</p></td><td><p>-1.01</p></td><td><p>-0.16</p></td><td><p>Beat</p></td><td><p>84.1</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td></td><td><p>-5.04</p></td><td><p>-0.77</p></td><td><p>Beat</p></td><td><p>84.8</p></td></tr><tr><td><p>Dec. 31 2022</p></td><td><p>-9.60</p></td><td><p>-9.60</p></td><td><p>-14.56</p></td><td><p>Missed</p></td><td><p>-51.7</p></td></tr></tbody></table><p>This summary was machine generated November 8 at 15:48 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroBo Pharmaceuticals Inc  expected to post a loss of 89 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroBo Pharmaceuticals Inc  expected to post a loss of 89 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 23:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF24Z:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NeuroBo Pharmaceuticals Inc  expected to post a loss of 89 cents a share - Earnings Preview NeuroBo Pharmaceuticals Inc NRBO.OQ NRBO.O is expected to show no change in quarterly revenue when it ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF24Z:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRBO","symbol_name":"NeuroBo Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF24Z:1","article_id":"2481932483","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481932483","pubTimestamp":1731080958,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeuroBo Pharmaceuticals Inc  expected to post a loss of89cents a share - Earnings Preview NeuroBo Pharmaceuticals Inc NRBO.OQ NRBO.O is expected to show no change in quarterly revenue when it reports ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NRBO":"NeuroBo Pharmaceuticals, Inc."},"translate_title":"NeuroBo Pharmaceuticals Inc预计每股亏损89美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRBO":0.9},"content_text":"NeuroBo Pharmaceuticals Inc  expected to post a loss of 89 cents a share - Earnings Preview NeuroBo Pharmaceuticals Inc NRBO.OQ NRBO.O is expected to show no change in quarterly revenue when it reports  results  for the period ending December 31 2024LSEG's mean analyst estimate for NeuroBo Pharmaceuticals Inc is for a loss of 89 cents per share. The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts had risen by about 22.1% in the last three months. Wall Street's median 12-month price target for NeuroBo Pharmaceuticals Inc is $22.00, above its last closing price of $2.68. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Jan. 1 0001-0.77-0.73-0.55Beat24.7Jan. 1 0001-1.06-1.12-1.85Missed-64.7Mar. 31 2024-3.79-3.63-1.32Beat63.6Dec. 31 2023-0.79-0.78-2.28Missed-190.4Jan. 1 0001-0.86-0.86-0.72Beat15.9Jun. 30 2023-1.01-1.01-0.16Beat84.1Mar. 31 2023-5.04-0.77Beat84.8Dec. 31 2022-9.60-9.60-14.56Missed-51.7This summary was machine generated November 8 at 15:48 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481932483"}